



# BRITISH-AMERICAN TOBACCO COMPANY LTD

A member of the B·A·T Industries Group

Registered Office:  
PO Box 482 Westminster House  
7 Millbank London SW1P 3JE  
Telephone: 01-222 1222  
Telex: 27384 BATFOR G

RESTRICTED

RET/FL

7th June 1989

NOTE FOR MR A.L. HEARD

R.P.G. CANADA

Strategic issues that should be discussed:

1. Scientific Issues

Possible impact of recent scientific research on the BAT Group business:

- a) cancer research, especially molecular biology.
- b) free radicals.
- c) epidemiology, including ETS.

These are areas in which outside speakers could make a contribution. The following may be appropriate:

- a) Dr John Jenkins (Marie Curie Memorial Foundation).
- b) Professor Bruce Ames (University of Berkeley, California).
- c) Professor T.D. Sterling and associates, (Vancouver, Canada).

This could then be followed by a discussion on the implications and appropriate response by BAT (see also proposed item 4). Since these are "industry" issues, how do we collaborate with other tobacco companies?

2(a) Regulatory Issues

Additives What overall policy should the Group have on additives, noting:

- a) possible development in the USA.
- b) EEC action on other Regulatory issues.
- c) any other group inputs.

Incorporated in London Number 74974 Cables: Vehicular London SW1

401096801

Mr A.L. Heard, 7th June 1989

What is the role of the AGP in relation to the Company's duty of care?

2(b) Standard Smoking Methods Implications for Group of introduction of new ISO method. How would "Premier" have been treated had it been a successful launch.

3. Environmental Issues

- a) What effect will the 'Green' movement have on BAT Group business? e.g. on use of additives and on ETS.
- b) To what extent do other industries have similar potential problems (as tobacco) and are they friends or enemies? Should we seek common ground with such companies?
- c) How does "Premier" and other novel designs relate to these issues?
- d) How proactive should we be on ETS in countries where it is not yet a major issue?

4. Organisational Issues

How should the Group discharge its duty of care in respect of advancing scientific knowledge? In particular:-

- a) Should the S.R.G. continue to discharge this function?

or

- b) Should it be delegated to Corporate R&D Dept. Millbank

or

- c) To what extent should the R.P.G. itself get directly involved?
- d) In the light of any change in policy how with the S.R.G. activities be funded?

*Ray*  
R.E. Thornton

c.c. Dr S. Boyse, Millbank.

401096802